Navigation Links
DiscoveRx Corp. & Jubilant Biosys Limited Announce Co-Marketing Agreement for Screening Services

BANGALORE, India, January 11 /PRNewswire-FirstCall/ -- Jubilant Biosys Limited, based in Bangalore, an integrated Drug Discovery and Development solution provider, a subsidiary of Jubilant Organosys Ltd, headquartered in Noida, announced today that it has entered into a co-marketing agreement to provide screening solutions, with DiscoveRx Corporation (Fermont, USA), a premier provider of innovative cell based assay solutions for GPCR, Kinases, NHR and Proteases.

This agreement allows Jubilant access to DiscoveRx PathHunter(TM) and cAMPHunter(TM) cell lines and proprietary EFC chemiluminescent detection technology to perform screening on behalf of Jubilant's customers. The agreement also enables DiscoveRx to expand its platform technology to offer screening solutions from India.

DiscoveRx's PathHunter(TM) ss-Arrestin and HitHunter(TM) cAMP assays are homogeneous chemiluminescent assays which are rapidly becoming GPCR screening platform of choice for screening and profiling applications. Jubilant's demonstrated capabilities in discovery research state of the art medicinal chemistry, modeling, structural biology and screening facilities including High Throughput screening facility supported by automated compound management and visualization tools coupled with the DiscoveRx award winning assay platform offers global pharmaceutical companies access to cost effective screening and lead generation services that will enable and accelerate global drug discovery efforts.

Commenting on the Collaboration, Dr. Kailash Swarna, COO, Global Drug Discovery, at Jubilant Biosys said:

"We are pleased to announce this agreement with DiscoveRx, and look forward to the prospect of providing value to our customers using DiscoveRx PathHunter(TM) and HitHunter(TM) technologies. This partnership continues to demonstrate Jubilant's mission to partner with leading technology providers that provide access to cutting edge and innovative solutions to accelerate global drug discovery efforts with our collaborators."

Pyare Khanna, President and CEO, DiscoveRx Corporation says,

"DiscoveRx constantly strives to provide our truly innovative solutions to screening community. We are determined to help expedite the drug discovery processes and are delighted with this relationship with Jubilant. Our customers require an easy access to our innovative product portfolio and such partnerships will add value to our efforts of bringing industry leading portfolio of PathHunter(TM) and HitHunter(TM) GPCR assays to a broader audience."

About DiscoveRx Corporation

Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. The Company pioneered the use of B-galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases and other major drug target classes, and many of their innovative products have been widely adopted in pharmaceutical and biotech drug screening laboratories worldwide. The Company is also a recipient of two Frost and Sullivan 2008 awards: Award for Innovation in North American Healthcare Market as well as a European Product Line Strategy Award for it's GPCR Cell Based assay portfolio. For more information on DiscoveRx products, please visit

About Jubilant Biosys:

Jubilant Biosys Ltd., a subsidiary of Jubilant Organsys Ltd., provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has an integrated state of the art facility in Bangalore. The Center houses over 450 scientists specializing in multiple disciplines to include Discovery biology, medicinal chemistry, structural biology, pharmacology, toxicology, pharmacy chem., molecular modeling, crystallography and information technology supporting discovery efforts. For more information please visit:


    DiscoveRx Corporation
    Sailaja Kuchibhatla
    Sr. VP Business Development
    DiscoveRx Corp.
    +1-510-979-1415 ext. 104

    Jubilant Biosys Ltd.
    Esha Kakkar
    Executive - Corporate Planning
    Jubilant Biosys Ltd.
    Ph: +91-80-66628683

SOURCE Jubilant Biosys Ltd

SOURCE Jubilant Biosys Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences and DiscoveRx Announce Availability of PathHunter eXpress Reagents for GPCR Assays
2. Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization
3. Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director
4. AvidBiotics Corp. Granted Key U.S. and European Patents on Unique Protein Modification Platform
5. Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
6. BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
7. Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009
9. BioSpecifics Technologies Corp. Stock Trading Halted Today
10. BioSpecifics Technologies Corp. To Present at BioCentury NewsMakers in the Biotech Industry Conference
11. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 11th Annual Healthcare Conference
Post Your Comments:
(Date:11/30/2015)... Spherix Incorporated (Nasdaq: SPEX ) an ... and monetization of intellectual property, today provided an ... to create shareholder value. Anthony ... on published reports, the total addressable market of ... Spherix will seek to secure fair and reasonable ...
(Date:11/30/2015)...  HUYA Bioscience International, the leader in accelerating global ... today announced it has signed a Memorandum of Understanding ... collaboration between KDDF and HUYA with the ultimate goal ... for the global market. China,s ... innovative preclinical and clinical stage compounds. The company advances ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... MarkLogic, the Enterprise NoSQL database platform provider, creating a seamless approach to ... Content Intelligence capabilities provide a robust set of semantic tools which create ...
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is one ... biomarkers market with pharmaceutical companies and diagnostic ... diagnostic tests. . ... Complete report on global cancer biomarkers market ...
Breaking Biology Technology:
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
(Date:10/27/2015)... , Oct. 27, 2015 In the present ... of concern for various industry verticals such as banking, ... to the growing demand for secure & simplified access ... ,sectors, such as hacking of bank accounts, misuse of ... equipment such as PC,s, laptops, and smartphones are expected ...
Breaking Biology News(10 mins):